COMMUNIQUÉS West-GlobeNewswire
-
Advanced Radiation Centers of New York Launches SoftRay™ Therapy, Offering New Non-Surgical Relief of Inflammatory, Tendon and Arthritis Pain
14/04/2026 -
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
14/04/2026 -
Prenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One
14/04/2026 -
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
14/04/2026 -
Neion Bio Strengthens Genome Engineering Leadership with Appointment of Colossal Biosciences Veteran James Kehler
14/04/2026 -
Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods
14/04/2026 -
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
14/04/2026 -
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
14/04/2026 -
Nanox Announces Collaboration with Meir Medical Center to Deploy Nanox.ARC for Orthopedic Imaging Clinical Study
14/04/2026 -
GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026
14/04/2026 -
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
14/04/2026 -
R1 Announces Revenue Performance Solutions Powered by Phare OS to Help Providers Navigate Growing Complexity and Margin Pressure
14/04/2026 -
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay
14/04/2026 -
Aclarion Receives Pinnacle Award for AI Innovation
14/04/2026 -
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
14/04/2026 -
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
14/04/2026 -
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH
14/04/2026 -
Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease
14/04/2026 -
Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth
14/04/2026
Pages